Merck, Ra Pharma enter drug-development deal worth up to $200M

04/2/2013 | Pharmaceutical Business Review Online · Xconomy

Merck and Ra Pharmaceuticals agreed to collaborate in the development of Cyclomimetics drug candidates against multiple therapeutic areas using the latter's Extreme Diversity platform. Cyclomimetics are peptidelike molecules that have the diversity and specificity of antibodies. The deal entitles Ra to about $200 million in payments including upfront fee, research funding and milestone fees.

View Full Article in:

Pharmaceutical Business Review Online · Xconomy

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Paralegal, Legal-Regulatory
Confidential
Piscataway, NJ